Executive Director, Payer Strategy and Engagement (Tumor HI Program)

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.

Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

• Experience with rare/orphan drugs is required. Therapeutic area experience is a plus.
• Product launch experience is required, and company start-up experience is preferred.
• Familiarity with current legal and regulatory landscape pertinent to the pharmaceutical/biotechnology industry.
• Strong analytical capabilities, with working knowledge of government pricing practices (calculations methodologies, HTA, healthcare programs, and supporting regulations), and trade systems and processes.
• Demonstrated flexibility to adapt to a changing environment, implement creative solutions to complex problems, and ability to function in a project leadership role.
• Ability to develop and maintain strong internal and external relationships, including direct collaboration with vendors and other third parties.
• Superior interpersonal, oral and written communication, and presentation skills, with great attention to detail.
• Leads with strong business acumen and a compliance mindset.
• Passionate about patients and building a new commercial organization.
• Advanced Microsoft Excel, Word and PowerPoint skills. 

• Minimum Bachelor’s degree required; sciences or business preferred, advanced degree related medical, health economics, health outcomes research, or epidemiology (MS, MBA, MPH, MD/DO, PhD, PharmD) preferred.
• Minimum of 10 years of overall industry experience in biotech or pharmaceuticals (i.e. market access and reimbursement, sales, sales management, marketing, training, sales operations, or healthcare / life sciences consulting).
• 5 years of US market access and reimbursement experience required, with Global and/or international experience preferred.  This includes, HTA, US Payer, Patient and Provider access, HEOR, and medical benefit reimbursement coding expertise.

 

Rezolute (RZLT) currently anticipates the base salary for the Executive Director, Payer Strategy and Engagement role could range from $290,000 to $320,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience and geographical location of the selected candidate.

This role is based in the home office and requires minimum of 3 days per week in the office.

Qualifying employees are eligible to participate in benefit programs such as:

• Health Insurance (Medical / Dental / Vision)
• Disability, Life & Long-Term Care Insurance
• Holiday Pay
• Tracking Free Vacation Program
• 401(k) Plan Match
• Educational Assistance Benefit